Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2024 6
2025 240
2026 100

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

311 results

Results by year

Filters applied: . Clear all
Page 1
Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death.
Humbert M, McLaughlin VV, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, Preston IR, Souza R, Waxman AB, Moles VM, Savale L, Vizza CD, Rosenkranz S, Shi Y, Miller B, Mackenzie HS, Kim SS, Loureiro MJ, Patel MJ, Koglin J, Cornell AG, Hoeper MM; ZENITH Trial Investigators. Humbert M, et al. N Engl J Med. 2025 May 29;392(20):1987-2000. doi: 10.1056/NEJMoa2415160. Epub 2025 Mar 31. N Engl J Med. 2025. PMID: 40167274 Clinical Trial.
A long-term follow-up study of sotatercept for treatment of pulmonary arterial hypertension: interim results of SOTERIA.
Preston IR, Badesch D, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Humbert M, McLaughlin VV, Waxman AB, Manimaran S, Mikhailova E, Reddy M, Lau A, de Oliveira Pena J, Souza R. Preston IR, et al. Eur Respir J. 2025 Jul 24;66(1):2401435. doi: 10.1183/13993003.01435-2024. Print 2025 Jul. Eur Respir J. 2025. PMID: 39978862 Free PMC article.
Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis.
McLaughlin VV, Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, Preston IR, Souza R, Waxman AB, Kopeć G, Meyer G, Olsson KM, Fu W, Shi Y, Miller B, Kim SS, Mackenzie HS, Brambatti M, Patel MJ, Koglin J, Cornell AG, Humbert M; HYPERION Trial Investigators. McLaughlin VV, et al. N Engl J Med. 2025 Oct 23;393(16):1599-1611. doi: 10.1056/NEJMoa2508170. Epub 2025 Sep 30. N Engl J Med. 2025. PMID: 41025556 Clinical Trial.
Drugs targeting novel pathways in pulmonary arterial hypertension.
Sitbon O, Boucly A, Weatherald J, Antigny F, Guignabert C, Jevnikar M, Jaïs X, Price LC, Wilkins MR, Zamanian RT, Savale L, Montani D, Humbert M. Sitbon O, et al. Eur Respir J. 2025 Aug 8;66(2):2401830. doi: 10.1183/13993003.01830-2024. Print 2025 Aug. Eur Respir J. 2025. PMID: 40341051 Review.
EP4/ANXA2 axis in pulmonary arterial hypertension: therapeutic implications.
Xu H, Ye L, Du C, Tang H, Zheng Q, Zhu C, Liang B, Wang Y, Mao X, Liang Q, Zhang J, Shao H, Sun X, Yuan R, Yun W, Luo C, Xiu J, Su W, Fan F, Dai Z, Chen L, Guan Y, Zhang X. Xu H, et al. Eur Heart J. 2026 Mar 9;47(10):1199-1217. doi: 10.1093/eurheartj/ehaf763. Eur Heart J. 2026. PMID: 40996819
Positioning Imatinib for Pulmonary Arterial Hypertension: A Dose-Finding Phase 2 Study.
Rothman AMK, Villar SS, Middleton J, Roussakis AA, Varian F, Zafar H, Law M, Apperley J, Bartelink IH, Said MM, Delgado-SanMartin JA, Kiely DG, Howard L, Toshner M, Wort SJ, Wilkins MR. Rothman AMK, et al. Am J Respir Crit Care Med. 2025 Jun;211(6):1018-1027. doi: 10.1164/rccm.202410-1929OC. Am J Respir Crit Care Med. 2025. PMID: 40080796 Free PMC article. Clinical Trial.
Initial therapy in patients with pulmonary arterial hypertension and cardiovascular comorbidities.
Boucly A, Montani D, Bauer F, Artaud-Macari E, Bergot E, Boissin C, Chaouat A, Cottin V, Dauphin C, Degano B, De Groote P, du Roure C, Favrolt N, Horeau-Langlard D, Jaïs X, Jevnikar M, Lacoste-Palasset T, Picard F, Prévôt G, Reynaud-Gaubert M, Roche A, Turquier S, Humbert M, Sitbon O, Savale L. Boucly A, et al. Eur Respir J. 2025 May 6;65(5):2400895. doi: 10.1183/13993003.00895-2024. Print 2025 May. Eur Respir J. 2025. PMID: 39884763
311 results